• Introduction
• Scope and Methodology
• Size and Growth of the Market
• Issues and Trends Affecting Market
• Leading Competitors

Chapter Two: Introduction

• Overview of the Cardiovascular System
  • Heart
  • Circulatory System
  • Cardiac Cycle
  • Coronary Circulation
  • Cardiac Myocytes
  • Contraction
  • Cardiac Energy Metabolism
  • Cardiac Output
  
  
• Cardiovascular Disorders
  • Angina
  • Arrhythmias
  • Atherosclerosis
  • Congestive Heart Failure
  • Coronary Artery Disease
  • Hypertension
  • Myocardial Infarction
  
  
• Effects of Aging
• Demographics
• Disease Management

Chapter three: Issues and Trends

• Immediate Statin Use Investigated
• Clinical Trial Image
• Inflammation reduction
• Unique Drug Combinations
• Antihypertensive Blockbuster
• OTC Statins

chapter Four: Prescription Cardiac Glycoside and Iontropic Drugs

• Overview of Cardiac Glycosides and Inotropic Drugs
• Description of Products
• Market Size and Growth
  • World Market
  • The U.S. Market
  • Non-U.S. Market
  
  
• Research and Development
• Competitive Analysis

Chapter Five: Prescription Antihypertensive Drugs

• Overview
• Description of Products
  • ACE Inhibitors
  • Angiotensin II Receptor Antagonists
  • Adrenergic Blockers
  • Beta Blockers
  • Calcium Channel Blockers
  • Combinations
  
  
• Market Size and Growth
  • World Market
  • U.S. Market
  • Non-U.S. Market
  
  
• Research and Development
• Competitive Analysis

chapter Six: Prescription Antiarrhythmic Drugs

• Overview
• Description of Products
  • Class I
  • Class II
  • Class III
  
  
• Market Size and Growth
  • World Market
  • U.S. Market
  • Non-U.S. Market
  
  
• Research and Development
• Competitive Analysis

chapter Seven: Prescription Vasodilator and Peripheral Vasodilator Drugs

• Overview
• Description of Products
  • Coronary Vasodilators
  • Natriuretic Peptides
  • Peripheral Vasodilators
  
  
• Market Size and Growth
  • World Market
  • U.S. Market
  • Non-U.S. Market
  
  
• Research and Development
• Competitive Analysis

Chapter Eight: Prescription Antihyperlipidemic Drugs

• Overview
• Description of Products
  • Bile Acid Sequestrants
  • Fibric Acid Derivatives
  • HMG-CoA Reductase Inhibitors (Statins)
  • Nicotinic Acid
  
  
• Market Size and Growth
  • World Market
  • U.S. Market
  • Non-U.S. Market
  
  
• Research and Development
• Competitive Analysis

chapter nine: Prescription Blood Modifiers

• Overview
• Description of Products
  • Anticoagulants
  • Antiplatelets
  • Thrombolytics
  
  
• Market Size and Growth
  • World Market
  • U.S. Market
  • Non-U.S. Market
  
  
• Research and Development
• Competitive Analysis

chapter ten: Prescription Diuretic Drugs

• Overview
• Description of Products
  • Carbonic Anhydrase Inhibitors
  • Loop
  • Potassium-Sparing
  • Thiazides
  
  
• Market Size and Growth
  • World Market
  • U.S. Market
  • Non-U.S. Market
  
  
• Research and Development
• Competitive Analysis

chapter eleven: Prescription Other Cardiovascular Drugs

• Overview
• Description of Products
• Market Size and Growth
  • World Market
  • U.S. Market
  • Non-U.S. Market
  
  
• Research and Development
• Competitive Analysis

Chapter twelve: World Market Summary

• Overview
• Total market Size and Forecast
• Competitive Analysis

Chapter thirteen: Corporate Profiles

• Abbott Laboratories
• Astrazeneca
• Astrazeneca
• Bayer Corporation
• Biovail Corporation
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Genentech, Inc.
• GlaxoSmithKline
• Merck & Company Inc
• Novartis International AG
• Pfizer, Inc.
• Roche
• Sankyo Pharmaceuticals
• Sanofi-Aventis
• Schering-Plough
• Wyeth

Appendix A: Selected Emerging Cardiovascular Company Briefs

• Cardiome Pharma Corporation
• Myogen
• Vasogen

Appendix B: Company Directory

List of Exhibits

chapter one: Executive Summary

• Table 1-1: Total World Prescription Cardiovascular Drug Market 2002-2009
• Figure 1-1: Total World Prescription Cardiovascular Drug Market 2002-2009
• Table 1-2: Top 17 Prescription Cardiovascular Drug Marketers: Cardiovascular Revenues and Segments of Participation 2004

chapter two: Introduction

• Table 2-1: U.S. Prevalence, Incidence and Mortality of Selected Cardiovascular Conditions

chapter four: Prescription Cardiac Glycoside and Iontropic Drugs

• Table 4-1: Currently Marketed Cardiac Glycosides and Inotropic Drugs
• Table 4-2: Total World Market for Cardiac Glycoside and Inotropic Drugs 2002-2009
• Figure 4-1: World Cardiac Glycoside and Inotropic Drug Market 2002-2009
• Table 4-3:Total U.S. Market for Cardiac Glycoside and Inotropic Drugs 2002-2009
• Figure 4-2: Total U.S. Cardiac Glycoside and Inotropic Drug Market 2002-2009
• Table 4-4: Total Non-U.S. Market for Cardiac Glycoside and Inotropic Drugs 2002-2009
• Figure 4-3: Total Non-U.S. Cardiac Glycoside and Inotropic Drug Market 2002-2009
• Table 4-5: Cardiac Glycosides and Inotropic Agents in Development
• Table 4-6: Cardiac Glycoside and Inotropic Drug Revenues and Market Share by Supplier 2004
• Figure 4-4: Total Global Market for Cardiac Glycoside & Inotropic Drugs, Market Share by Leading Supplier 2004

chapter five: Prescription Antihypertensive Drugs

• Table 5-1: Currently Marketed ACE Inhibitors
• Table 5-2: Currently Marketed Angiotensin II Receptor Antagonists
• Table 5-3: Currently Marketed Adrenergic and Beta Blockers
• Table 5-4: Currently Marketed Calcium Channel Blockers
• Table 5-5: Currently Marketed Combination Antihypertensives
• Table 5-6: Total World Market for Prescription Antihypertensive Drugs 2002-2009
• Figure 5-1: Total World Market for Prescription Antihypertensive Drugs 2002-2009
• Table 5-7: World Market for Prescription Antihypertensive Drugs by Type (ACE Inhibitors, Angiotensin II Receptor Antagonists, Adrenergic Blockers, Beta Blockers, Calcium Channel Blockers, and Combinations) 2002-2009
• Figure 5-2: Total World Prescription Antihypertensive Drug Market by Type 2002-2009
• Table 5-8: Total U.S. Prescription Antihypertensive Drug Market 2002-2009
• Figure 5-3: Total U.S. Prescription Antihypertensive Drug Market 2002-2009
• Table 5-9: Total Non-U.S. Prescription Antihypertensive Drug Market 2002-2009
• Figure 5-4: Total Non-U.S. Prescription Antihypertensive Drug Market 2002-2009
• Table 5-10: Hypertensive Drugs in Development
• Table 5-11: Global Prescription Antihypertensive Drug Revenues and Market Share by Leading Supplier 2004
• Figure 5-6: Global Prescription Antihypertensive Drug Market Share by Leading Supplier 2004

chapter six: Prescription Antiarrhythmic Drugs

• Table 6-1:Currently Marketed Antiarrhythmic Drugs
• Table 6-2: World Market for Prescription Antiarrhythmic Drugs 2002-2009
• Figure 6-1: Total World Prescription Antiarrhythmic Drug Market 2002-2009
• Table 6-3: U.S. Market for Prescription Antiarrhythmic Drugs 2002-2009
• Figure 6-2: Total U.S. Prescription Antiarrhythmic Drug Market 2002-2009
• Table 6-4: Total Non-U.S. Prescription Antiarrhythmic Drug Market 2002-2009
• Figure 6-3: Total Non-U.S. Prescription Antiarrhythmic Drug Market 2002-2009
• Table 6-5: Antiarrhythmic Drugs in Development
• Table 6-6: Global Prescription Antiarrhythmic Drugs Revenues and Market Share by Leading Supplier 2004
• Figure 6-3: Global Prescription Antiarrhythmic Drug Market Share by Leading Supplier 2004

chapter seven:Prescription Vasodilator and Peripheral Vasodilator Drugs

• Table 7-1: Currently Marketed Vasodilator and Peripheral Vasodilator Drugs
• Table 7-2: World Market for Vasodilator and Peripheral Vasodilator Drugs 2002-2009
• Figure 7-1: World Market for Vasodilator and Peripheral Vasodilator Drugs 2002-2009
• Table 7-3: Total U.S. Vasodilator and Peripheral Vasodilator Drugs Market 2002-2009
• Figure 7-2: Total U.S. Vasodilator and Peripheral Vasodilator Drugs Market 2002-2009
• Table 7-4: Total Non-U.S. Vasodilator and Peripheral Vasodilator Drugs Market 2002-2009
• Figure 7-3: Total Non-U.S. Vasodilator and Peripheral Vasodilator Drugs Market 2002-2009
• Table 7-5: Vasodilator and Peripheral Vasodilator Drugs in Development
• Table 7-6: Global Vasodilator and Peripheral Vasodilator Drug Revenues and Market Share by Leading Supplier 2004
• Figure 7-4: Global Vasodilator and Peripheral Vasodilator Drug Market Share by Leading Supplier 2004

chapter eight: Prescription Antihyperlipidemic Drugs

• Table 8-1: Currently Marketed Antihyperlipidemic Drugs
• Table 8-2: World Market for Antihyperlipidemic Drugs 2002-2009
• Figure 8-1: World Prescription Antihyperlipidemic Drugs Market 2002-2009
• Table 8-3: U.S. Market for Prescription Antihyperlipidemic Drugs 2002-2009
• Figure 8-2: U.S. Prescription Antihyperlipidemic Drugs Market 2002-2009
• Table 8-4: Non-U.S. Market for Prescription Antihyperlipidemic Drugs 2002-2009
• Figure 8-3: Total Non-U.S. Prescription Antihyperlipidemic Drugs Market 2002-2009
• Table 8-4:Antihyperlipidemic Drugs in Development
• Table 8-5: Global Prescription Antihyperlipidemic Drug Revenues and Market Share by Leading Supplier 2004
• Figure 8-4: Global Prescription Antihyperlipidemic Drug Market Share by Leading Supplier 2004

chapter nine: Prescription Blood Modifiers

• Table 9-1: Currently Marketed Anticoagulant Drugs
• Table 9-2: Currently Marketed Antiplatelet Drugs
• Table 9-3: Currently Marketed Thrombolytic Drugs
• Table 9-4: World Market for Prescription Blood Modifier Drugs 2002-2009
• Figure 9-1: Total World Prescription Blood Modifier Drug Market 2002-2009
• Table 9-5: U.S. Prescription Blood Modifier Drug Market 2002-2009
• Figure 9-2: U.S. Prescription Blood Modifier Drug Market 2002-2009
• Table 9-6: Non-U.S. Prescription Blood Modifier Drug Market 2002-2009
• Figure 9-3: Non-U.S. Prescription Blood Modifier Drug Market 2002-2009
• Table 9-7: Global Market for Prescription Blood Modifier Drugs by Type (Anticoagulants, Antiplatelets, Thrombolytics) 2002-2009
• Figure 9-4: The Global Market for Prescription Blood Modifier Drugs Revenues by Type 2002-2009
• Table 9-8: Blood Modifier Drugs in Development
• Table 9-9: Global Prescription Blood Modifier Revenues and Market Share by Leading Supplier 2004
• Figure 9-5: Global Prescription Blood Modifier Drug Market Share by Leading Supplier 2004

chapter ten: Prescription Diuretic Drugs

• Table 10-1: Currently Marketed Diurectic Drugs
• Table 10-2: World Market for Prescription Diuretic Drugs 2002-2009
• Figure 10-1: World Market for Prescription Diuretic Drugs 2002-2009
• Table 10-3: U.S. Prescription Diuretic Drugs Market 2002-2009
• Figure10-2: U.S. Prescription Diuretic Drugs Market 2002-2009
• Table10-4: Non-U.S. Prescription Diuretic Drugs Market 2002-2009
• Figure 10-3: Non-U.S. Prescription Diuretic Drugs Market 2002-2009
• Table 10-5: Diuretic Drugs in Development
• Table 10-6: Global Prescription Diuretic Drug Revenues and Market Share by Leading Supplier 2004
• Figure 10-4: Total Global Market for Prescription Diuretic Drugs, Market Share by Leading Supplier 2004

chapter eleven: Prescription Other Cardiovascular Drugs

• Table 11-1: Currently Marketed Other Cardiovascular Drugs
• Table 11-2: World Market for Other Cardiovascular Drugs 2002-2009
• Figure 11-1: World Market for Other Cardiovascular Drugs 2002-2009
• Table 11-3: U.S. Market for Other Cardiovascular Drugs 2002-2009
• Figure 11-2: U.S. Market for Other Cardiovascular Drugs 2002-2009
• Table 11-4: Non-U.S. Market for Other Cardiovascular Drugs 2002-2009
• Figure 11-3: Non-U.S. Market for Other Cardiovascular Drugs 2002-2009
• Table 11-5: Other Cardiovascular Drugs in Development
• Table 11-6: World Market for Other Cardiovascular Drugs Revenues and Market Share by Leading Supplier 2004
• Figure 11-4: Total World Market for Other Cardiovascular Drugs Market Share by Leading Supplier 2004

Chapter twelve: World Market Summary

• Table 12-1: Total World Market for Prescription Cardiovascular Drugs 2002-2009
• Table 12-2: World Market for Prescription Cardiovascular Drugs by Product Segment 2002-2009
• Figure 12-3: World Prescription Cardiovascular Drug Market by Product Segment 2002-2009
• Figure 12-4: The World Market for Prescription Cardiovascular Drugs Market Share by Product Segment 2004
• Table 12-3: World Market for Prescription Cardiovascular Drugs Revenues and Segments of Participation by Major Areas of Participation 2004

Chapter thirteen: Corporate Profiles
Appendix A: Selected Emerging Cardiovascular Company Briefs
Appendix B: Company Directory